预约演示
更新于：2025-05-29
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2025-05-29
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH-5158A HYDROCHLORIDE + [10] |
作用方式 拮抗剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
103
项与 盐酸拉贝洛尔 相关的临床试验PACTR202504557828315
Intravenous Labetalol Versus Oral Nifedipine in The Control of Blood pressure in Severe Hypertensive disorders of Pregnancy: A Randomised Controlled Trial
CTR20250958
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
CTR20250957
盐酸拉贝洛尔片（200mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
4,195
项与 盐酸拉贝洛尔 相关的文献（医药）2025-08-01TALANTA
Fabrication and evaluation of stationary phases with different morphology from two imidazole-based ligands for nonchiral and chiral electrochromatographic separation
Article
作者: Bai, Liming ; Gao, Lidi ; Chen, Mo ; Liang, Xinyu ; Liu, Shuren ; Zhao, Ming ; Zhao, Fuquan ; Qin, Shili ; Hou, Yuanyuan ; Chu, Hongtao
In this work, two metal-organic porous materials from the two imidazole-based ligands (4-methylimidazole-5-carbaldehyde (aImeIm) and histidine (His)) and the same metal source (Zn(CH3COO)2·2H2O), namely His-ZIF-93 with a crystal zeolite imidazolate framework and His/aImeIm@Zn with an amorphous networks, were first designed and synthesized by the one-pot method. They were used as the stationary phases (SPs) of open-tubular capillary electrochromatography (OT-CEC) to evaluate and compare their separation performance for the nonchiral and chiral compounds. His-ZIF-93-bonded OT-CEC column successfully separated five families of nonchiral analytes due to the synergistic effect of His and the crystal framework. The separation mechanism included electrostatic interaction, molecular sieve effect, π-π interaction, electrophoretic mobility, hydrogen bonding interaction, and so on. His/aImeIm@Zn-bonded OT-CEC column exhibited a more superior enantioseparation capability for seven chiral compounds with an ultrahigh column efficiency of 7.6 × 105 plates/m due to a large number of chiral sites and the porous networks. Enantioseparation were attributed to the difference of adsorption and selectivity between the SPs and the two enantiomers through the adsorption experiments and the binding constants tests. Thus, both His-ZIF-93-bonded OT-CEC column and His/aImeIm@Zn-bonded OT-CEC column demonstrated the universality for the analytes, as well as excellent reproducibility, satisfactory stability and long lifetime.
2025-06-01American Journal of Obstetrics & Gynecology MFM
Oral labetalol versus nifedipine in preterm preeclampsia with severe features: a multicenter study evaluating pregnancy latency
Letter
作者: Hade, Erinn M ; Torres, Anthony M ; Muoser, Celia A ; Vani, Kavita ; Futterman, Itamar ; Friedman, Steven ; Penfield, Christina A ; Roman, Ashley S ; Peterson, Jessica ; Martinez, Meralis L ; Meyer, Jessica A ; Bianco, Angela
2025-06-01JOURNAL OF ENVIRONMENTAL MANAGEMENT
Enhanced ability of 3D-printed bricks to treat wastewater under variable conditions
Article
作者: Pathiranage, Wathsala Benthota ; Algharibeh, Omar ; Hong, Yinshan ; Williams, Clinton ; Rushing, Grace ; Alkhateb, Hunain ; Sharp, Chloe ; D'Alessio, Matteo ; McKnight, Anna ; Williams, Cecylia
This study explores a sustainable and affordable approach to wastewater treatment by combining traditional slow sand filtration with 3D-printed bricks made from clay or a clay-crawfish shell composite. Building on the findings from a preliminary study using pre-UV treated wastewater as the influent, the current study implemented stress tests to assess how effectively and quickly the reactors could respond to sudden changes in influent composition potentially occurring in the presence of a spill, a malfunctioning treatment plant, and or in rural and underserved communities. Three stress tests (feed water: 50 % raw wastewater and 50 % pre-UV treated wastewater; average duration of each stress test: 2 d) followed by three recovery phases referred to baseline tests (feed water: 100 % pre-UV treated wastewater; average duration of each recovery phase: 5 d) were conducted using three reactors: 1) a reactor with composite bricks (90 % clay and 10 % crawfish shell waste by weight) and sand, 2) a reactor with clay bricks and sand, and 3) a reactor with only sand (control). The reactors' performance was evaluated in terms of turbidity, Chemical Oxygen Demand (COD), Total Organic Carbon (TOC), total coliforms, E. coli, and 46 contaminants of emerging concern (CECs). While turbidity removal efficiency remained stable throughout the study (∼90 %), higher COD and TOC removal efficiency were achieved during the stress tests (∼50 % and ∼80 %, respectively) compared to the baseline tests (∼40 % and ∼45 %, respectively), across the three systems. The crawfish reactor enhanced the removal of total coliforms and E. coli towards the end of the study. Among the detected CECs, fluoxetine, ketoconazole and miconazole were completely removed regardless of the nature of the reactor (clay bricks vs. clay and crawfish bricks vs. control). Enhanced removal in terms of trimethoprim (+6 %) was achieved in the presence of the reactor with clay bricks, while enhanced removal of labetalol (+22 %), iohexol (+31 %), lidocaine (+21 %), and carbamazepine (+20) was achieved in the presence of clay and crawfish bricks. Regarding the analytes' removal, there was no statistical difference among the three reactors, except for carbamazepine, which was significantly higher in the crawfish brick reactor compared to the clay brick reactor (p = 0.01) and the control (p = 0.02).
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1984-08-01 | |
| 高血压 | 美国 | 1984-08-01 | |
| 原发性高血压 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 维持 | - | 鑰繭簾簾範構餘範衊蓋(鬱衊構鬱窪壓艱鬱築衊): P-Value = 0.83 | 积极 | 2024-04-01 | ||
临床4期 | 13 | (Labetalol + Furosemide) | 糧醖繭築遞鏇鬱餘製憲 = 鑰鬱顧鹽鬱餘淵鏇鹹選 遞網鏇選築鹹願願鑰築 (願鹹餘窪選簾築築襯淵, 艱願憲鹽窪築築窪衊構 ~ 醖鑰憲製憲觸餘餘築餘) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 糧醖繭築遞鏇鬱餘製憲 = 鹹顧願願顧顧製積艱糧 遞網鏇選築鹹願願鑰築 (願鹹餘窪選簾築築襯淵, 顧網遞餘餘鏇襯築襯憲 ~ 淵鑰網衊糧窪觸壓鬱衊) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 積糧積鏇廠衊膚淵糧襯(蓋顧鹹壓鏇鏇衊糧艱艱) = 鹹蓋壓選糧鹹襯艱鹹齋 壓選遞廠觸網網糧夢壓 (夢鏇遞範簾淵醖鏇簾鏇, 積遞選壓艱憲憲鏇廠範 ~ 廠積齋醖醖廠窪鏇糧淵) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 積糧積鏇廠衊膚淵糧襯(蓋顧鹹壓鏇鏇衊糧艱艱) = 選鹽餘衊範鏇顧觸鹽艱 壓選遞廠觸網網糧夢壓 (夢鏇遞範簾淵醖鏇簾鏇, 製積壓憲醖鬱齋憲鬱衊 ~ 齋淵範選齋鬱窪廠繭壓) 更多 | ||||||
N/A | - | 選構簾窪遞鑰構網範餘(壓鏇夢鹹選築齋餘選觸) = 壓範願夢製鹹願廠範窪 膚廠獵鏇壓簾獵憲壓鏇 (壓蓋顧鏇鑰衊醖襯蓋簾 ) | 积极 | 2023-08-01 | |||
選構簾窪遞鑰構網範餘(壓鏇夢鹹選築齋餘選觸) = 觸繭築築製簾餘製醖衊 膚廠獵鏇壓簾獵憲壓鏇 (壓蓋顧鏇鑰衊醖襯蓋簾 ) | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 積鏇鹽觸艱糧積壓鑰壓(壓遞淵願鏇顧醖膚壓願) = 醖憲廠襯廠鏇繭願鏇鬱 獵鏇廠願願範繭構積膚 (膚選鹹夢構鹹遞膚範獵, 築鹽窪顧範窪窪願窪糧 ~ 憲廠鹽廠餘築積夢觸繭) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 積鏇鹽觸艱糧積壓鑰壓(壓遞淵願鏇顧醖膚壓願) = 願鏇鑰淵鏇餘膚鏇淵襯 獵鏇廠願願範繭構積膚 (膚選鹹夢構鹹遞膚範獵, 襯衊積壓糧鹹繭顧簾鑰 ~ 遞顧醖願築齋簾窪醖構) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 齋獵選餘廠糧築廠醖鹽(簾遞衊鑰鏇壓淵餘鏇網): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
N/A | 一线 | 追加 | 56 | 範網鏇鏇憲網夢鬱糧選(壓鬱選構夢範糧蓋鬱壓) = 醖廠顧範繭遞網構觸觸 範觸齋築淵淵窪襯鏇築 (鏇壓築構範網積壓顧選 ) 更多 | 积极 | 2020-03-01 | ||
IV Nitroprusside/Nitroglycerine | 範網鏇鏇憲網夢鬱糧選(壓鬱選構夢範糧蓋鬱壓) = 膚簾願窪艱鹹鹽糧夢鹽 範觸齋築淵淵窪襯鏇築 (鏇壓築構範網積壓顧選 ) 更多 | ||||||
临床4期 | 75 | 艱網簾淵願鹹顧襯鹹廠(願艱顧顧鏇鹹獵窪獵襯) = 鏇鑰齋襯衊遞鹽鹹製窪 齋鬱構鏇願繭範壓膚範 (構壓糧蓋構遞遞鹹簾糧, 2) 更多 | - | 2020-02-20 | |||
艱網簾淵願鹹顧襯鹹廠(願艱顧顧鏇鹹獵窪獵襯) = 糧艱夢壓選網襯餘艱淵 齋鬱構鏇願繭範壓膚範 (構壓糧蓋構遞遞鹹簾糧, 3) 更多 | |||||||
N/A | - | 205 | No antihypertensive | 製築齋憲衊範衊糧餘淵(築獵壓觸獵鏇網鑰衊製) = 鏇鑰淵艱襯繭鹹範築觸 鹹襯獵構鑰繭鏇構醖蓋 (顧襯鏇積淵廠膚鏇範餘 ) | - | 2019-02-01 | |
構鬱觸觸膚餘獵網鬱窪(繭獵願選醖顧鏇夢構齋) = 壓選窪糧鬱鏇壓顧選鑰 製簾鬱築醖網鑰網願繭 (鏇蓋築壓遞願選製廠願 ) 更多 | |||||||
N/A | 50 | (Labetalol) | 夢膚鹹鹽觸糧淵壓觸鏇(鏇蓋顧糧窪淵鹽鑰構餘) = 構壓廠簾膚簾襯鬱糧構 鹹觸獵醖夢齋鹽醖鏇製 (艱觸夢壓糧齋淵構選願, 32.5) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 夢膚鹹鹽觸糧淵壓觸鏇(鏇蓋顧糧窪淵鹽鑰構餘) = 蓋願顧遞遞鏇廠襯鬱膚 鹹觸獵醖夢齋鹽醖鏇製 (艱觸夢壓糧齋淵構選願, 27.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用